Stocks To Buy Forum

Stocks to Buy based on the Best Stock Market Research

John James
  • Male
  • Frankfurt
  • Germany
Share

John James's Discussions

RDHL (MC $150 M) $60+ M Cash / 3 MEGA Drugs with P3 results in 1H 2017
1 Reply

RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap…Continue

Started this discussion. Last reply by John James Dec 27, 2016.

AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP
2 Replies

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry…Continue

Started this discussion. Last reply by John James yesterday.

IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
5 Replies

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA…Continue

Started this discussion. Last reply by John James Aug 22, 2016.

IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!
1 Reply

IPCI has a very large and attractive Product Pipeline with 8 Drugs awaiting FDA approval which could they could approved anytime now . Their Key Drug is Rexista a potential Best in Class Abuse…Continue

Started this discussion. Last reply by John James Jun 23, 2016.

 

John James's Page

Latest Activity

John James replied to John James's discussion RDHL (MC $150 M) $60+ M Cash / 3 MEGA Drugs with P3 results in 1H 2017
"Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering) RedHill Expects An Eventful Next Few Months…"
Dec 27, 2016
John James posted a discussion

RDHL (MC $150 M) $60+ M Cash / 3 MEGA Drugs with P3 results in 1H 2017

RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .Market Cap :$148 MillionCash: $62 MillionPrice: 9.70Shares out 15 Million (50% of Shares…See More
Dec 22, 2016
John James posted a discussion

AQSZF (MC $10 M) 2 Marketed Drugs & 3 Drugs nearing Approval = FANTASTIC OPP

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in…See More
Sep 21, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Shorts tried hard to kill momentum yesterday but they will lose the Game because the Stock is terrible Undervalued und there is to much News on the way so every dip below $1 is a great buying opportunity . IntelGenx Technologies Corp…"
Aug 9, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"IGXT start moving get some before she explodes higher ,Big News like Partnership(s),NDA submissions and new approvals in EU on the way . Market cap of $35 Million is more than ridiculous .Fair Value is minimum…"
Aug 1, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Here is one of the reason why i like this stock so much is because of this  thin-flim version of the Blockbuster Cialis which works faster than tablet . There are NO generics available on the Markets so IGXT could capture a significant market…"
Jul 27, 2016
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Strong Insider & Institutional Ownership on this Goldmine . Big Jump to new highs could come anytime now .GLInsider Ownership : Horst G. Zerbe 4,670,243.5 7.34% Ingrid Zerbe 5,471,356.5 8.60% Bernard J. Boudreau 287,500 Bernd Melcher 232,500…"
Jul 26, 2016
John James posted a discussion

IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there is another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .IGXT has a ridiculous Market Cap of less than $32 Million which is a Big Joke for a…See More
Jul 21, 2016
John James replied to John James's discussion IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!
"once the stock retake the MA(50) at 1.80 then quick jump back over $2 coming . IPCI is still one of the most undervalued Biotechs out there [img]http://finviz.com/chart.ashx?t=IPCI&ty=c&ta=1&p=d&s=l[/img]"
Jun 23, 2016
John James posted a discussion

IPCI (MC $44 M) 8 Drugs awaiting FDA approval =1000%+ Potential !!!

IPCI has a very large and attractive Product Pipeline with 8 Drugs awaiting FDA approval which could they could approved anytime now . Their Key Drug is Rexista a potential Best in Class Abuse Deterrent  Pain Drug with HUGE Market Potential . NDA Filing for the Drug is planned within Weeks (June or July) .We could see $5++ easily with NDA filing and Runup to FDA decision (4Q16 or early 1Q2017) and much higher if there is any approval of the Drugs under review by FDA . This ultra Low float Stock…See More
Jun 2, 2016
John James replied to John James's discussion AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+ BILLION Market)
"Aytu is definitely oneof the cheapest Biotechs out there but this will change quickly once investors discover this Goldmine .GLAYTU – Expanding Men’s Urology Portfolio...... By Zacks Small Cap ResearchMay 25, 2016 4:30…"
May 27, 2016
John James posted a discussion

AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+ BILLION Market)

Here is an undiscovered Stock with Monster Upside Potential  which just trading at cash level . Aytu Biosciences bought US Rights to Natesto the only [b]approved[/b] testosterone nasal gel which targets a $2+ BILLION Market which they start selling in July . The Company has another 3 Products on the Market and another One Big drug ready for Phase 3 . AYTU has a ridiculous Market Cap of just $13 Million which is below the Cash balance of $15 Million means you get the Company and Products for…See More
May 26, 2016
John James replied to John James's discussion INNV (MC $4 M) 13 Products on Market +BIG FDA approval in 1H 2016
"Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN) http://finance.yahoo.com/news/upcoming-pdufa-anda-approval-dates-140000806.html Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13…"
May 16, 2016
John James replied to John James's discussion INNV (MC $4 M) 13 Products on Market +BIG FDA approval in 1H 2016
"New Recommendation SeeThruEquity Issues Update Note on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) with a Price Target of $0.80http://finance.yahoo.com/news/seethruequity-issues-note-innovus-pharmaceuticals-130000823.html"
Apr 19, 2016
John James replied to John James's discussion INNV (MC $4 M) 13 Products on Market +BIG FDA approval in 1H 2016
"Nice move and the market-cap is still around $12 Million . Fair Value is 0.60-0.80 by now and much higher if they get FDA approval by mid year . http://stockcharts.com/c-sc/sc?s=innv&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658"
Apr 14, 2016
John James replied to John James's discussion INNV (MC $4 M) 13 Products on Market +BIG FDA approval in 1H 2016
"more infos.... $INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues https://www.youtube.com/watch?v=f7YnqjVLVg0 In the interview, Dr. Damaj highlighted short-term goals for Innovus Pharma, which includes: 1.…"
Apr 13, 2016

Comment Wall

You need to be a member of Stocks To Buy Forum to add comments!

Join Stocks To Buy Forum

  • No comments yet!
 
 
 

Stocks to Buy 2017

Stocks to Buy 2017

Small Cap Bull 3x (TNA)
Shake Shack (SHAK)
Stocks to Watch - 2017
Penny Stocks - 2017



Twitter - Free Stock Alerts

© 2017   Created by Stocks To Buy.   Powered by

Badges  |  Report an Issue  |  Terms of Service